What is Fate Therapeutics, Inc.'s Market Cap?

Fate Therapeutics, Inc.'s Market Cap is $299.6M, based on as-reported figures from SEC (XBRL) filings.

What is Fate Therapeutics, Inc.'s Enterprise Value?

Fate Therapeutics, Inc.'s Enterprise Value is $145.8M, based on as-reported figures from SEC (XBRL) filings.

What is Fate Therapeutics, Inc.'s Price / Sales?

Fate Therapeutics, Inc.'s Price / Sales is 46.1×, based on as-reported figures from SEC (XBRL) filings.

What is Fate Therapeutics, Inc.'s EV / Revenue?

Fate Therapeutics, Inc.'s EV / Revenue is 22.5×, based on as-reported figures from SEC (XBRL) filings.

What is Fate Therapeutics, Inc.'s EV / EBITDA?

Fate Therapeutics, Inc.'s EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.

What is Fate Therapeutics, Inc.'s Revenue (TTM)?

Fate Therapeutics, Inc.'s Revenue (TTM) is $6.5M, based on as-reported figures from SEC (XBRL) filings.

What is Fate Therapeutics, Inc.'s Net Income (TTM)?

Fate Therapeutics, Inc.'s Net Income (TTM) is -$126.0M, based on as-reported figures from SEC (XBRL) filings.

What is Fate Therapeutics, Inc.'s EBITDA?

Fate Therapeutics, Inc.'s EBITDA is -$121.6M, based on as-reported figures from SEC (XBRL) filings.

What is Fate Therapeutics, Inc.'s Diluted EPS (TTM)?

Fate Therapeutics, Inc.'s Diluted EPS (TTM) is -1.05, based on as-reported figures from SEC (XBRL) filings.

What is Fate Therapeutics, Inc.'s EBITDA Margin?

Fate Therapeutics, Inc.'s EBITDA Margin is -1873.4%, based on as-reported figures from SEC (XBRL) filings.

Fate Therapeutics, Inc. (FATE) Financial Statements

Fate Therapeutics, Inc.

SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

FIGI BBG001T888S2

XNAS · usd

2.50▲ 0.02 (0.81%)

As of 2026-09-08

Valuation

Market Cap

Enterprise Value

Trailing P/E—

Price / Sales

EV / Revenue

EV / EBITDA

Financial Highlights

Revenue (TTM)

Net Income (TTM)

EBITDA

Diluted EPS (TTM)

EBITDA Margin

Net Debt

Trading Information

Previous Close2.48

Day's Range2.40 – 2.55

52-Week Range0.93 – 3.23

Volume1.9M

Avg Volume1.8M

Share Statistics

Shares Outstanding

Employees161

ExchangeXNAS

Listed2013-10-01

Share count as of August 6, 2026

ViewDetail

Period

Loading Income Statement…

Key questions about Fate Therapeutics, Inc. (FATE)

What is Fate Therapeutics, Inc.'s Market Cap?: Fate Therapeutics, Inc.'s Market Cap is $299.6M, based on as-reported figures from SEC (XBRL) filings.
What is Fate Therapeutics, Inc.'s Enterprise Value?: Fate Therapeutics, Inc.'s Enterprise Value is $145.8M, based on as-reported figures from SEC (XBRL) filings.
What is Fate Therapeutics, Inc.'s Price / Sales?: Fate Therapeutics, Inc.'s Price / Sales is 46.1×, based on as-reported figures from SEC (XBRL) filings.
What is Fate Therapeutics, Inc.'s EV / Revenue?: Fate Therapeutics, Inc.'s EV / Revenue is 22.5×, based on as-reported figures from SEC (XBRL) filings.
What is Fate Therapeutics, Inc.'s EV / EBITDA?: Fate Therapeutics, Inc.'s EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Fate Therapeutics, Inc.'s Revenue (TTM)?: Fate Therapeutics, Inc.'s Revenue (TTM) is $6.5M, based on as-reported figures from SEC (XBRL) filings.
What is Fate Therapeutics, Inc.'s Net Income (TTM)?: Fate Therapeutics, Inc.'s Net Income (TTM) is -$126.0M, based on as-reported figures from SEC (XBRL) filings.
What is Fate Therapeutics, Inc.'s EBITDA?: Fate Therapeutics, Inc.'s EBITDA is -$121.6M, based on as-reported figures from SEC (XBRL) filings.
What is Fate Therapeutics, Inc.'s Diluted EPS (TTM)?: Fate Therapeutics, Inc.'s Diluted EPS (TTM) is -1.05, based on as-reported figures from SEC (XBRL) filings.
What is Fate Therapeutics, Inc.'s EBITDA Margin?: Fate Therapeutics, Inc.'s EBITDA Margin is -1873.4%, based on as-reported figures from SEC (XBRL) filings.